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Continuing Education Reminders
A total of 20 contact hours of continuing education 
(CE) must be completed by December 31 of each calendar 
year. Unless specified, each condition below is a yearly 
requirement.
 ♦ Only a maximum of eight contact hours per calendar 
day will be accepted.
 ♦ At least five contact hours must be “live.” Visit http://
elearning.ashp.org/acpe-designations for help in 
determining whether a webinar would be considered 
“live.”
 ♦ At least two contact hours must be in the area of 
pharmacy law. It does not need to be “live,” nor does 
it have to be specific to Massachusetts.
 ♦ Pharmacists involved in a collaborative drug therapy 
management (CDTM) agreement must complete at 
least five additional contact hours (ie, total of 25 con-
tact hours yearly) that address topics related to their 
general practice areas.
 ♦ Pharmacists who are engaged in or oversee sterile 
compounding activities must complete five contact 
hours in the area of sterile compounding.
 ♦ Pharmacists who are engaged in or oversee complex 
nonsterile compounding activities must complete 
three contact hours on this topic. An advisory that 
reviews the levels of nonsterile compounding is avail-
able at www.mass.gov/eohhs/docs/dph/quality/boards/
pharmacy/advisories/advisory-non-sterile.pdf.
 ♦ Beginning January 1, 2017, immunizing pharmacists 
must complete one contact hour every other year in 
the area of vaccination.
The Massachusetts Board of Registration in Pharmacy 
accepts three types of credit: Accreditation Council for 
Pharmacy Education (ACPE), continuing medical education 
Category 1, and Board-approved programs. Currently, only 
ACPE-accredited continuing pharmacy education (CPE) 
credit is stored in CPE Monitor®; therefore, certificates of 
completion must be retained for the other approved program 
types. Pharmacists must retain documentation of completed 
CE hours for at least two years.
All pharmacists, including nonresident pharmacists 
practicing in other states, must complete the immunization, 
CDTM, compounding, and other CE requirements if they 
oversee or engage in these practices.
For more information regarding compounding CE cri-
teria and other CE information, please visit www.mass 
.gov/eohhs/docs/dph/quality/boards/pharmacy/alerts/
pharmacist-continuing-education.pdf.
Common Inspectional Deficiencies
Refrigerators with internal freezers (eg, dorm-style) 
are not permitted. The ice buildup affects the internal 
temperature, causing unacceptable variations. Remember 
that food and beverages may not be placed in any refrig-
erators or freezers that are used for medication storage. 
Review Board policy 2011-01 for more details: www.mass 
.gov/eohhs/docs/dph/quality/boards/pharmacy/pharmacy-
policy-2011-01-fridge.pdf.
All returned-to-stock medication should be appropri-
ately labeled with the product name, strength, and expiration 
date assigned at the time of filling. It is also vital to remove 
patient-sensitive information, including the prescription 
number. It should be assumed that any returned-to-stock 
bottle that does not have a lot number on the label would 
be included in the event of a recall.
Perpetual inventory must be performed at least once 
every 10 days. In addition to remaining on the perpetual 
inventory, all expired or damaged controlled substances must 
remain in a secure location (eg, safe) until they are returned.
Compounding pharmacies must retain master formula-
tion records and compounding logs for each compounded 
product. Compounded products may only be dispensed with 
valid patient-specific prescriptions.
Mid-Level Practitioner Prescriptions
Prescriptions issued by nurse practitioners, psychiatric 
nurses, nurse anesthetists, or pharmacists must include 
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In a Just Culture, HR-related policies and procedures regard-
ing safety should hold all individuals equally accountable for the 
quality of their  behavioral choices and should not focus on errors 
(which are not a behavioral choice), except for the expectation to 
report them. Policies and procedures should reflect a tone that is 
proactive toward risk identification, rather than reactive to errors 
and adverse outcomes. They should define human error as inad-
vertent, with a response of consoling individuals and conducting 
an investigation to determine how to redesign systems to prevent 
errors or detect them before reaching the patient. Policies and 
procedures should describe how to investigate a procedural vio-
lation to determine its causes and scope, and how to coach staff 
who have engaged in at-risk behaviors under the mistaken, but 
good faith, belief that the risks were insignificant or justified. For 
outcome-based duties related to a business code of conduct, such 
as arriving to work on time and wearing identification badges, 
policies should be clear about expectations and the actions that 
will be taken when they are not met. When describing reckless 
behavior (actions involving a conscious disregard of what an 
individual knows is a substantial and unjustifiable risk), remove 
any reference to “negligent” or “criminal” conduct as the basis 
for disciplinary action. Regrettably, mere human error can result 
in legal action (criminal negligence), but human error is never 
reckless behavior. Also ensure that event reporting and investiga-
tion policies and procedures support the tenets of a Just Culture. 
While HR-related policies and procedures cannot guarantee 
that the desired actions will be realized in practice, they are a 
critical step for building an organizational foundation for success. 
Old punitive policies risk slipping back into an unjust culture. As 
organizations align actual practice with a Just Culture, they also 
need to align supporting policies and procedures.
AMA Task Force to Reduce Opioid Abuse 
Promotes Safe Storage, Disposal of Opioids
The American Medical Association (AMA) Task Force to 
Reduce Opioid Abuse released a resource document that urges 
physicians and other health care providers to promote safe storage 
and disposal of opioids and all medications. The AMA document 
indicates physicians and other providers need to:
♦ educate patients about safe use of prescription opioids;
♦ remind patients to store medications out of children’s reach
in a safe place; and
♦ talk to patients about the most appropriate way to dispose
of expired, unwanted, and unused medications.
The AMA resource document and additional information can be 
found at www.ama-assn.org/opioids-disposal. Options for dispos-
ing of medications safely are available in the Initiatives section 
of the NABP website at www.nabp.pharmacy under AWARXE®. 
CDC Guide Shows Importance of Physicians, 
Pharmacists Working Together
Collaborative care by at least two practitioners working together 
with the patient to accomplish shared goals has been shown to improve 
hypertension control and cholesterol management, especially when the 
team involves a physician or nurse and a pharmacist, notes a new guide 
developed by the Centers for Disease Control and Prevention (CDC) 
Division for Heart Disease and Stroke Prevention, in collaboration 
with the American Pharmacists Association and AMA. The guide, 
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.Pharmacy Domain Signals Safety on the Web 
With only 4% of websites selling pre-
scription drugs online following United 
States pharmacy laws and practice stan-
dards, consumers seeking medications 
online are faced with the daunting task of finding a safe site. 
To assist consumers and those legitimate pharmacies with an 
online presence, NABP has streamlined its website verification 
programs. As of September 1, 2017, NABP is only offering the 
.Pharmacy Verified Websites Program and the Verified Internet 
Pharmacy Practice Sites® (VIPPS®) program, providing an easy 
choice for safety-minded consumers and pharmacies alike. The 
.Pharmacy Program, which was launched in 2014, enables quali-
fied pharmacies and pharmacy-related businesses to register a 
web address with the .pharmacy domain. A .pharmacy domain 
(pronounced “dot pharmacy”) is part of a website’s address like 
“.com” or “.biz”: www.safe.pharmacy. It enables people to iden-
tify an online pharmacy or pharmacy-related website as safe and 
legitimate. Since .pharmacy is a verified domain, websites are 
evaluated against a set of safety standards before an applicant is 
approved to register the domain. 
In addition to showing patients that they operate a safe website, 
the .pharmacy domain allows pharmacies and related entities to 
advertise online through Google, Bing, and Yahoo! The .Pharmacy 
Program replaces the e-Advertiser Approvalcm and Veterinary-
VIPPS® programs for those entities that are not eligible to apply 
for VIPPS but want to advertise with the search engines. 
For more information about the .Pharmacy Program, including the 
application and domain name registration process and fees, visit www 
.safe.pharmacy/apply.
Quality Processes, Risk Management, and 
Culture: HR-Related Policies That Conflict 
With a Just Culture
This column was prepared by the 
Institute for Safe Medication Practices 
(ISMP). ISMP is an independent nonprofit 
agency and federally certified patient safety 
organization that analyzes medication errors, near misses, and 
potentially hazardous conditions as reported by pharmacists 
and other practitioners. ISMP then makes appropriate contacts 
with companies and regulators, gathers expert opinion about 
prevention measures, and publishes its recommendations. To 
read about the risk reduction strategies that you can put into 
practice today, subscribe to ISMP Medication Safety Alert!® 
Community/Ambulatory Care Edition by visiting www.ismp.org. 
ISMP provides legal protection and confidentiality for submitted 
patient safety data and error reports. Help others by reporting 
actual and potential medication errors to the ISMP National 
Medication Errors Reporting Program Report online at www 
.ismp.org. Email: ismpinfo@ismp.org.
As health care organizations move toward a “Just Culture,” one of 
the areas potentially overlooked is human resource (HR)-related poli-
cies and procedures. Because these policies and procedures typically 
describe staff expectations, individual accountability, and disciplinary 
processes, they must be reviewed and often revised to ensure align-
ment with the tenets of a Just Culture. Otherwise, the journey will be 
long and unsuccessful if the policies are in conflict with a Just Culture. 
National Pharmacy Compliance News
The applicability of articles in the National Pharmacy Compliance News to a particular state or jurisdiction can only be ascertained 
by examining the law of such state or jurisdiction.
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Creating Community-Clinical Linkages Between Community 
Pharmacists and Physicians, discusses the importance of community-
clinical linkages specific to community pharmacists and physicians 
and provides a framework for how community pharmacists and 
physicians might approach the development of a link to help patients. 
In addition, the guide provides examples of existing community-
clinical linkages between community pharmacists and physicians 
and discusses common barriers to and potential solutions for creating 
community-clinical linkages. The guide is available at www.cdc 
.gov/dhdsp/pubs/docs/ccl-pharmacy-guide.pdf.
FIP Report Shows Value of Pharmacists’ Role 
in Consumers’ Self-Care
Support from pharmacists will assist consumers in better health 
maintenance and greater health system efficiency, indicates a 
recently released report from the International Pharmaceutical 
Federation (FIP). The report, Pharmacy as a gateway to care: 
Helping people towards better health, discusses the various factors 
involved in individual self-care and the evidence that pharmacists 
can increase value for those individuals through many opportunities 
because informed, engaged, and educated consumers will play a 
greater and critical role in caring for themselves. The definition of 
self-care this report adopts is that of the World Health Organization: 
“the ability of individuals, families and communities to promote 
health, prevent disease, and maintain health, and to cope with illness 
and disability with or without the support of a health care provider.” 
The report is available at www.fip.org/files/fip/publications/2017-
04-Pharmacy-Gateway-Care.pdf.
FDA Restricts Use of Codeine and Tramadol 
Medicines in Children; Recommends Against 
Use in Breastfeeding Women
As of April 2017, Food and Drug Administration (FDA) is 
restricting the use of codeine and tramadol medicines in children. 
FDA is also recommending against the use of these medicines in 
breastfeeding mothers due to possible harm to their infants. Codeine 
and tramadol medicines carry serious risks, including slowed or 
difficult breathing and death, which appear to be a greater risk 
in children younger than 12 years, and should not be used in this 
age group. These medicines should also be limited in some older 
children. Single-ingredient codeine and all tramadol-containing 
products are FDA-approved only for use in adults.
As indicated in the FDA Drug Safety Communication avail-
able at www.fda.gov/Drugs/DrugSafety/ucm549679.htm, FDA is 
requiring several changes to the labels of all prescription medicines 
containing these drugs. These new actions further limit the use of 
these medicines beyond their 2013 restriction of codeine use in 
children younger than 18 years to treat pain after surgery from 
removal of tonsils and/or adenoids. FDA is now adding:
 ♦ A  Contraindication to the drug labels of codeine and trama-
dol, alerting that codeine should not be used to treat pain or 
cough and tramadol should not be used to treat pain in children 
younger than 12 years.
 ♦ A  new Contraindication to the tramadol label, warning 
against its use in children younger than 18 years to treat pain 
after surgery from removal of tonsils and/or adenoids.
 ♦ A new Warning to the drug labels of codeine and tramadol to 
recommend against their use in adolescents between 12 and 
18 years who are obese or have conditions such as obstructive 
sleep apnea or severe lung disease, which may increase the 
risk of serious breathing problems.
 ♦ A strengthened Warning to mothers that breastfeeding is not 
recommended when taking codeine or tramadol medicines due 
to the risk of serious adverse reactions in breastfed infants.
FDA urges health care providers to report side effects involving 
codeine- and tramadol-containing medicines to the FDA MedWatch 
program at www.fda.gov/safety/medwatch. 
AVMA Warns Pharmacists and Pet Owners 
About Xylitol Pharmaceutical Products
Pharmaceutical products containing xylitol may be dangerous 
and fatal to dogs, warns the American Veterinary Medical Associa-
tion (AVMA). Xylitol stimulates an insulin release that can result 
in severe hypoglycemia and fatal liver damage. Pharmacists and 
pet owners need to be aware of and protect against xylitol toxi-
coses, indicates AVMA. FDA-approved gabapentin capsules and 
tablets do not contain xylitol, but the liquid form does. In addition, 
xylitol-containing media might be used in compounding products 
if the pharmacist is uninformed about not using it. 
AVMA urges pharmacists to not use xylitol-containing products 
when compounding for canine patients and to contact the veteri-
narian if a prescribed product contains xylitol. The veterinarian 
may be unaware that this sweetener is in the product. AVMA also 
encourages pet owners and caretakers to verify with the pharmacist 
when picking up their dog’s medication at a human pharmacy that 
the medication does not contain xylitol. Xylitol-containing peanut 
butter should not be used to help a dog take its medication.
For more information, visit atwork.avma.org/2017/05/30/
eliminate-xylitol-from-canine-prescriptions.
CDC Publishes Guide to Help Pharmacists 
Initiate CPAs With Prescribers
CDC published a guide that provides pharmacists with infor-
mation and resources to empower them to initiate collaborative 
practice agreements (CPAs) with collaborating prescribers. The 
guide, Advancing Team-Based Care Through Collaborative Practice 
Agreements: A Resource and Implementation Guide for Adding 
Pharmacists to the Care Team, contains a sample CPA and sample 
language that can be customized by pharmacists and prescribers 
using their specific state laws to create a CPA. The guide includes 
an overview of state laws, including which states currently allow 
CPAs. The guide is available at www.cdc.gov/dhdsp/pubs/docs/
CPA-Team-Based-Care.pdf. 
DEA Releases New Edition of Drugs of Abuse 
Resource Guide
Drug Enforcement Administration (DEA) released the 2017 edi-
tion of Drugs of Abuse, A DEA Resource Guide, which serves as a 
resource on the most commonly abused and misused drugs in the 
US. The latest edition, which is an update to the 2015 publication, 
describes the consequences of drug use, a drug’s effects on the 
body and mind, overdose potential, origin, legal status, and other 
key facts. It also includes the most current information on new and 
emerging trends in drug misuse and abuse, including fentanyl, other 
opioids, and synthetic drugs. The 2017 edition can be found at www 
.dea.gov/pr/multimedia-library/publications/drug_of_abuse.pdf.
National Pharmacy Compliance News
The applicability of articles in the National Pharmacy Compliance News to a particular state or jurisdiction can only be ascertained  
by examining the law of such state or jurisdiction.
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the name of the supervising physician. Other mid-level 
practitioners (ie, physician assistants) are not required to 
include it. The physician’s signature is also not necessary. 
View the full regulation at www.mass.gov/eohhs/docs/dph/
regs/105cmr721.pdf.
Out-of-state Schedule II narcotic prescriptions from a 
contiguous state or from Maine must be written by a physi-
cian, except for those written for a long-term care facility 
(LTCF) patient. Massachusetts pharmacies may fill these 
Schedule II prescriptions as long as the medications are 
delivered directly to the LTCF.
Nonsterile Compounding
United States Pharmacopeia (USP) Chapter <795> 
classifies nonsterile compounding into three general cat-
egories: simple, moderate, and complex.
Simple compounding includes making products that 
either have a USP Chapter <795> monograph or are the 
subject of a peer-reviewed journal article with specific 
compounding details.
Moderate compounding includes making products 
that require special calculations or procedures to determine 
quantities, or making a preparation for which stability data 
for that specific formulation are not available.
Complex compounding includes making preparations 
that require special training, environment, facilities, equip-
ment, and procedures to ensure appropriate therapeutic 
outcomes.
Simple and moderate compounding are commonly per-
formed in typical retail settings and include such examples 
as “magic mouthwash” and captopril oral solution.
The Board does not consider simple reconstitution to be 
compounding.
See the Board’s advisory regarding nonsterile com-
pounding at www.mass.gov/eohhs/docs/dph/quality/boards/
pharmacy/advisories/advisory-non-sterile.pdf.
A memo that references Food and Drug Administration’s 
position on the compounding of commercially available  drugs 
may be viewed at www.mass.gov/eohhs/docs/dph/quality/
boards/pharmacy/compounding-commercial-drugs.pdf.
Investigational Drug Studies
Retail pharmacies may only participate in investigational 
drug studies if the principal investigator (PI) of the study 
submits a research Massachusetts Controlled Substances 
Registration (MCSR) application with the Drug Control 
Program requesting to include the pharmacy. Each research 
MCSR application that incorporates a retail pharmacy will 
be reviewed, and a pharmacy representative may be required 
to appear before the Board for clarification. The pharmacy 
must maintain all documents related to drug study participa-
tion on site for Board inspection. It is important to note that 
a research MCSR is only valid for one year and one study. If 
a study lasts longer than a year, a renewal MCSR application 
must be submitted by the PI. A separate research MCSR is 
required for each research study even if the PI is the same.
Pharmacy documents that must be submitted with the 
research MCSR application include:
1. On pharmacy letterhead, a signed statement from the 
pharmacy manager of record or designated pharmacist-
in-charge of the study, including the following:
a. Board license number(s);
b. Identification of each pharmacy site participating 
in the study;
c. Manner of prescription receipt by retail pharmacy; 
and
d. Detailed description of the pharmacy’s specific 
role in procuring, receiving, handling, storing, 
compounding, repackaging, labeling, record keep-
ing, dispensing of study medication(s) (eg, direct 
to patient, prescriber’s office), and/or any other 
responsibilities of the pharmacy in the study (eg, 
randomization, blinding).
2. Example of the product label(s)
3. Example of patient prescription(s)
4. List of specific Board regulations that conflict with 
practices included in the study protocol;
5. Signed attestation that the pharmacy maintains master 
formulation record(s) for all compounded medications 
involved in the study and that said master formulation 
record(s) complies with Board regulations and all USP 
chapters
Did You Know?
 ♦ You can email the Board with practice inquiries at 
Pharmacy.Admin@MassMail.State.MA.US. 
 ♦ Vitamin D2 (ergocalciferol) and vitamin D3 (cholecal-
ciferol) are not interchangeable. Obtain provider clarifica-
tion if there is any uncertainty. 
 ♦ A “retired” license status is now available for pharma-
cists. This is intended to be a permanent change, not 
an “inactive” status that can be easily reversed. The 
application may be found at www.mass.gov/eohhs/
gov/departments/dph/programs/hcq/dhpl/pharmacy/ 
licensing/applications-and-forms.html#misc.
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